drugset / Trial / NCT02864550

Oral Doxycycline for the Prevention of Syphilis in Men Who Have Sex with Men (DaDHS)

NCT02864550

Phase 4 Completed 52 enrolled British Columbia Centre for Disease Control
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Syphilis is a sexually transmitted infection (STI) disproportionately affecting gay, bisexual and other men who have sex with men (gbMSM), with the potential for significant sequelae - particularly in those who are Human Immunodeficiency Virus (HIV)-positive. Rising rates of this STI have prompted a search for novel prevention solutions. A recent pilot study of daily doxycycline prophylaxis demonstrated promise as a novel STI prevention tool. This innovative approach to STI prevention has solid clinical precedent, both from the HIV pre-exposure prophylaxis (PrEP) literature, as well as doxycycline's use as prophylaxis for other infections. The overarching goal of this project is to determine whether the daily use of doxycycline is an efficacious and acceptable intervention for syphilis prevention in high-risk, HIV-positive gbMSM.

Timeline

Start
2019-08-15
Primary completion
2024-04-05
Completion
2024-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxycycline Small molecule 100 mg Oral

Indications